Ontamalimab(Ontamalimab) - 药物靶点：MAdCAM-1_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

PF-00547659、PF-547659、SHP-647

+ [1]

靶点

MAdCAM-1

作用方式

抑制剂

作用机制

MAdCAM-1抑制剂(黏膜地址素细胞黏附分子-1抑制剂)

治疗领域

免疫系统疾病消化系统疾病其他疾病

在研适应症-

非在研适应症

溃疡性结肠炎克罗恩病肝纤维化+ [2]

原研机构

Pfizer Inc.

在研机构-

非在研机构

Shire Plc

Pfizer Inc.

Takeda Pharmaceutical Co., Ltd.

权益机构

Shire Pharmaceuticals LLC

Pfizer Inc.

最高研发阶段终止临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 10192198L

来源: *****

Sequence Code 10192207H

来源: *****

关联

14

项与 Ontamalimab 相关的临床试验

NCT07052682

/ Terminated临床1期

A Multicenter, Single-arm, Open-label, Phase 1b Study to Explore the Mechanism of Action and Evaluate the Safety of Ontamalimab in Participants With Nonalcoholic Steatohepatitis With Fibrosis Stage 1 Through 4

The main aim of this study is to evaluate the safety and tolerability of ontamalimab in participants with a liver disease called nonalcoholic steatohepatitis (NASH) or metabolic dysfunction-associated steatohepatitis (MASH) with scarring in the liver (fibrosis stage 1 to 4). The study will also check if there are any important changes in the body's health markers (biomarkers) from the beginning of the study to see if ontamalimab stops liver scarring and reduces inflammation of the liver.
Participants will be in the study for approximately up to 46 weeks.

开始日期2023-01-18

申办/合作机构

Takeda Pharmaceutical Co., Ltd.

LBCTR2019090238

/ Unknown status临床3期

A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects with Moderate to Severe Ulcerative Colitis - FIGARO UC 302

开始日期2019-11-01

申办/合作机构

Shire Human Genetic Therapies, Inc.

NCT03559517

/ Terminated临床3期

A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 305)

The purpose of this study is to evaluate the efficacy and safety of ontamalimab in inducing clinical remission and endoscopic response in participants with moderate to severe Crohn's Disease.

开始日期2018-08-29

申办/合作机构

Shire Plc

100 项与 Ontamalimab 相关的临床结果

登录后查看更多信息

100 项与 Ontamalimab 相关的转化医学

登录后查看更多信息

100 项与 Ontamalimab 相关的专利（医药）

登录后查看更多信息

27

项与 Ontamalimab 相关的文献（医药）

2025-07-01·CURRENT OPINION IN GASTROENTEROLOGY

Gut-directed therapeutics in inflammatory bowel disease

Review

作者: Ciorba, Matthew A. ; Curiel, David T. ; Kratschmer, Christina

Purpose of review:

Tissue-directed therapies (TDTs) provide potential advantages, including improved tolerance, safety, and efficacy. This review provides a conceptual framework for understanding intestinal TDT and summarizes the current landscape of TDT in inflammatory bowel disease (IBD).

Recent findings:

Vedolizumab, a mAb targeting the gut homing α4β7 integrin, served as revolutionary proof-of-principle for the power of advanced TDT in IBD. The development of other monoclonal antibodies targeting cell adhesion molecules followed including abrilumab (α4β7), etrolizumab (β7), and ontamalimab (MAdCAM-1). MORF-057, an oral small molecule inhibitor of α4β7, is now in development for ulcerative colitis. Efforts have also been made toward gut specific JAK inhibitors. Microbiome-based therapies, including engineered probiotics, bacteriophages, and postbiotics, are gaining interest. There are also a number of innovative drug delivery methods, including engineered yeast, hydrogels, and nanoparticles, and viral-based gene therapy.

Summary:

Gut-targeted therapies range from novel variations on traditional drugs (i.e., mAbs and small molecules) to microbiome-based therapeutics and engineered delivery systems. They can be used alone or in combination with currently available therapies. Future directions should focus on the development of tried-and-true modalities (mAbs, small molecules) as well as the microbiome and more innovative delivery systems.

2024-05-31·Journal of Crohn's & colitis

Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn’s Disease

Article

作者: Schreiber, Stefan ; Cataldi, Fabio ; Gorelick, Kenneth J ; D’Haens, Geert ; Reinisch, Walter ; Thakur, Manoj ; Sandborn, William J ; Goetsch, Martina ; Nagy, Peter ; Hanauer, Stephen ; Bliss, Caleb ; Vermeire, Séverine ; Danese, Silvio

Abstract:

Background and Aims:

Ontamalimab is a fully human immunoglobulin G2 monoclonal antibody against mucosal addressin cell adhesion molecule-1, developed as treatment for inflammatory bowel disease.

Methods:

Six phase 3, multicentre, randomised, double-blind, placebo-controlled clinical trials compared efficacy and safety of ontamalimab [25 mg and 75 mg once every 4 weeks] with placebo in patients with moderate-to-severe ulcerative colitis or Crohn’s disease [two induction studies and one re-randomised maintenance study per condition]. This clinical trial programme was discontinued in 2020 for reasons unrelated to drug safety/efficacy; Crohn’s disease studies are described in the Supplementary data.

Results:

The induction [12-week] and maintenance [52-week] studies included 659 and 366 randomised patients, respectively. More patients who received ontamalimab induction than placebo achieved the primary endpoint of clinical remission at Week 12 [25 mg, 18.5% vs 15.8%, p = 0.617, 27.0% vs 12.5%, p = 0.027; 75 mg, 29.8% vs 15.8%, p = 0.018, 29.5% vs 12.5% p = 0.014]; significantly more patients who received ontamalimab maintenance therapy than placebo achieved Week 52 clinical remission [25 mg, 53.5% vs 8.2%, p <0.001; 75 mg, 40.2% vs 12.8%, p <0.001]. Endoscopic improvement was generally significantly different vs placebo [induction: 25 mg, 27.8% vs 21.1%, p = 0.253, 35.1% vs 12.5%, p = 0.001; 75 mg, 41.1% vs 21.1%, p = 0.002, 33.9% vs 12.5%, p = 0.003; maintenance: 25 mg, 56.3% vs 9.6%, p <0.001; 75 mg, 48.8% vs 15.1%, p <0.001]. Adverse event rates were similar between ontamalimab and placebo groups.

Conclusions:

Ontamalimab 75 mg was effective, with no safety concerns, as induction and maintenance therapy for patients with moderate-to-severe ulcerative colitis. [NCT03259334; NCT03259308; NCT03290781; NCT03559517; NCT03566823; NCT03627091]

2023-11-24·Journal of Crohn's & colitis

Differential Effects of Ontamalimab Versus Vedolizumab on Immune Cell Trafficking in Intestinal Inflammation and Inflammatory Bowel Disease

Article

作者: Imke Atreya ; Arif B Ekici ; Raja Atreya ; Dan Sexton ; Philipp Kirchner ; Li-Juan Liu ; Mark Dedden ; Mariam Mohamed-Abdou ; TRR241 IBDome consortium ; Michael Stürzl ; Lisa Lou Schulze ; Britta Siegmund ; Maximilian Wiendl ; Deborah Palliser ; Markus F Neurath ; Moritz Leppkes ; Emily Becker ; Tanja M Müller ; Chiara van Passen ; Karen A M Ullrich ; Sebastian Zundler

Abstract:

Background and Aims:

The anti-MAdCAM-1 antibody ontamalimab demonstrated efficacy in a phase II trial in ulcerative colitis and results of early terminated phase III trials are pending, but its precise mechanisms of action are still unclear. Thus, we explored the mechanisms of action of ontamalimab and compared it to the anti-α4β7 antibody vedolizumab.

Methods:

We studied MAdCAM-1 expression with RNA sequencing and immunohistochemistry. The mechanisms of action of ontamalimab were assessed with fluorescence microscopy, dynamic adhesion and rolling assays. We performed in vivo cell trafficking studies in mice and compared ontamalimab and vedolizumab surrogate [-s] antibodies in experimental models of colitis and wound healing. We analysed immune cell infiltration under anti-MAdCAM-1 and anti-α4β7 treatment by single-cell transcriptomics and studied compensatory trafficking pathways.

Results:

MAdCAM-1 expression was increased in active inflammatory bowel disease. Binding of ontamalimab to MAdCAM-1 induced the internalization of the complex. Functionally, ontamalimab blocked T cell adhesion similar to vedolizumab, but also inhibited L-selectin-dependent rolling of innate and adaptive immune cells. Despite conserved mechanisms in mice, the impact of ontamalimab-s and vedolizumab-s on experimental colitis and wound healing was similar. Single-cell RNA sequencing demonstrated enrichment of ontamalimab-s-treated lamina propria cells in specific clusters, and in vitro experiments indicated that redundant adhesion pathways are active in these cells.

Conclusions:

Ontamalimab has unique and broader mechanisms of action compared to vedolizumab. However, this seems to be compensated for by redundant cell trafficking circuits and leads to similar preclinical efficacy of anti-α4β7 and anti-MAdCAM-1 treatment. These results will be important for the interpretation of pending phase III data.

11

项与 Ontamalimab 相关的新闻（医药）

2026-04-19

·康桥服务咨询

[阳性对照] 中重度UC Ⅲ期临床研究

研究标题：评价HZBio2治疗中国成人中重度活动性溃疡性结肠炎患者的有效性和安全性的多中心、随机、双盲、阳性对照、平行设计的Ⅲ期研究 CDE登记号：CTR20252645 研究药物介绍： HZBio2 为维得利珠单抗（安吉优 ®）生物类似药，精准肠道靶向抗炎；Ⅰ/Ⅱ 期与原研药疗效、安全、PK 高度等效；Ⅲ 期阳性对照研究，数据可靠，适合中重度活动性 UC 患者入组获益。研究设计：分组：随机比例：1:1 试验组：注射用 HZBio2（300mg）阳性对照组：注射用维得利珠单抗（300mg，安吉优 ®）给药途径：静脉输注剂量：300mg / 次给药时间点：第 0、2、6、14、22、30、38、46 周主要终点：第 52 周临床缓解率患者一句话肖像： 18–80 岁，确诊 UC ≥3 个月，中重度活动性，传统治疗或 TNF-α 抑制剂应答不佳 / 失应答 / 不耐受。关键入排：入选 1.年龄18–80 岁，确诊UC ≥ 3 个月； 2.中重度活动性UC：Mayo 评分 6–12 分，内镜评分 ≥2 分； 3.病变累及直肠近端≥15cm； 4.对激素/ 5-ASA / 免疫抑制剂 / TNF-α 抑制剂应答不足、失应答或不耐受。排除 1.既往使用过维得利珠单抗、抗整合素类、MAdCAM-1 拮抗剂、利妥昔单抗； 2.近60 天 / 5 个半衰期内用过其他生物制剂； 3.严重感染、结核阳性、乙肝/ 丙肝 / HIV / 梅毒阳性； 4.近4 周内重大手术、活疫苗接种； 5.实验室指标明显异常（Hb<8g/dL、WBC<3×10⁹/L、肝肾功能超标等）。合并用药洗脱和禁忌要求：需对以下至少一类药物应答不足 / 失应答 / 不耐受药物类别代表药物糖皮质激素泼尼松、泼尼松龙、甲泼尼龙、布地奈德 5‑氨基水杨酸（5‑ASA）美沙拉嗪、奥沙拉嗪、巴柳氮、柳氮磺吡啶免疫抑制剂硫唑嘌呤、6‑巯基嘌呤、环孢素、他克莫司、甲氨蝶呤 TNF‑α 抑制剂英夫利昔单抗、阿达木单抗、戈利木单抗排除药物排除药物类别具体药品名称维得利珠单抗维得利珠单抗（安吉优 ®）抗整合素类药物那他珠单抗、依法利珠单抗、依曲利珠单抗、AMG‑181 MAdCAM‑1 拮抗剂 Ontamalimab (SHP647)、PF‑00547659 利妥昔单抗利妥昔单抗（抗 CD20）

2025-11-01

·药事纵横

武田：砍掉4条管线！押注中国创新

声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。武田制药近日公布2025财年上半年（4月至9月）业绩报告，期内营收为2.2万亿日元（约合143亿美元），较去年同期下滑约4%。为扭转局面，武田一方面大刀阔斧地削减早期研发管线，精简布局；另一方面则战略性押注中国创新，本月与信达生物的一笔首付高达12亿美元的重磅交易。半年度业绩承压，明星产品遭冲击武田上半年的业绩下滑主要源于旗下神经科学领域主力产品在美国市场遭遇强劲的仿制药竞争，以及不利的汇率影响。营业利润2536亿日元，同比下滑27.7%，净利润1124亿日元，同比下滑40%，经营现金流5937亿日元，同比增加31.6%。其中，注意力缺陷多动障碍（ADHD）药物Vyvanse 销售额受冲击最为显著，同比大幅下降46%至6.93亿美元。另一款ADHD药物Adderall XR 销售额也下降33%至6880万美元。此外，其抗抑郁药物Trintellix 则因美国医疗保险Part D计划的调整，销售额下降7%至3.70亿美元。武田制药管理层已更新全年指引，维持按固定汇率计算的收入"基本持平"的展望，但由于交易性外汇不利因素，将核心营业利润和核心每股收益预期修订为"低个位数百分比下降"。此外还将调整后自由现金流指引从之前的7500-8500亿降至6000-7000亿日元。管线精简，持续瘦身面对业绩压力，为应对挑战，武田正通过一系列果断的管线调整来优化研发投入，包括终止多项早期研发项目，并将资源聚焦于更具潜力的后期管线。其中，与阿斯利康共同开发的多系统萎缩候选药物TAK-341，因二期临床研究未达主要终点而终止合作。同时，出于内部“战略考量”，公司也决定停止两款处于一期阶段的候选药物——发作性睡病药物TAK-925与急性髓系白血病细胞疗法TAK-012的研发。此外，作为“产品组合优先排序”的结果，非酒精性脂肪性肝炎（MASH）资产TAK-647也被移出管线。此举也反映了当前MASH赛道竞争异常激烈、研发门槛高企的现状。图：武田管线更新表这一系列“瘦身”举措并非孤立事件，而是武田多年战略转型的延续。其核心目的在于集中资源，投向最具市场潜力的领域。接连的“瘦身”动作，无疑为武田省下了宝贵的研发资金。图：武田制药研发管线携手信达、和黄积极开拓增量在通过内部“瘦身”聚焦核心管线的同时，武田正积极通过外部合作开拓新的增长曲线，而这一战略的关键落点，正是来自中国的创新力量。本月，武田与信达生物达成一项重磅授权合作，以高达12亿美元的首付款，引进了两款极具市场潜力的晚期阶段资产： IBI363（PD-1/IL-2双抗）：一款已进入III期临床的潜在“重磅炸弹”。根据武田的评估，其瞄准的市场机会超过400亿美元，尤其在IO耐药非小细胞肺癌、一线非小细胞肺癌和一线结直肠癌领域空间广阔。 IBI343（CLDN18.2 ADC）：一款已做好III期临床准备的抗体偶联药物，主要针对CLDN18.2阳性的胃癌与胰腺癌患者，潜在市场规模约80亿美元。这笔交易不仅为武田的肿瘤管线注入了强劲动力，也印证了其对中国创新研发实力的高度认可。而信达生物自身的业绩增长同样亮眼，其2025年第三季度总产品收入超33亿元人民币，同比保持约40%的强劲增长。武田此次押注的IBI363面临的是PD-1后时代异常拥挤的赛道，其差异化优势究竟有多大，仍需临床数据进一步验证。这笔高达12亿美元首付款的交易，究竟是物有所值还是溢价过高，也成为了业界关注的焦点。然而，武田与中国药企的合作并非首次。与和黄医药合作，由武田负责海外商业化的呋喹替尼在2025年7-9月增长表现亮眼，海外销售额达0.97亿美元，同比提升34%。特别是在欧洲市场，销售额同比激增200%，日本市场环比增长82%，成为武田全球管线中一个亮眼的增长点。总结武田的“加减法”展现了一家跨国药企在专利悬崖下的典型突围路径。将中国创新从“可选项”变为“必选项”的策略，不仅为国内Biotech打了强心针，也预示着全球医药创新的力量对比正在发生深刻转变。这一趋势不仅印证了中国本土研发质量的飞跃，也为更多中国新药研发公司通过授权合作等模式走向全球，提供了可供借鉴的现实路径。未来的挑战或许在于如何将这些重金引入的资产成功推向全球市场，希望中国本土Biotech都能陆续走向世界。参考资料： www.takeda.com innoventbio.com www.hutch-med.com endpoints.news

财报孤儿药临床2期细胞疗法

2025-10-30

·EndPoints

Takeda makes some pipeline cuts, says generic competition softens Q2 sales

Takeda said Thursday it has ended work on several early- and mid-stage drug candidates, adding that its second quarter sales took a hit from “generic erosion” and “unfavourable” exchange rates. The Japanese drugmaker nixed an AstraZeneca-partnered candidate for multiple system atrophy called TAK-341 after it missed the primary and secondary endpoints in a Phase 2 trial, according to a financial report . It also terminated two Phase 1 programs for narcolepsy (TAK-925) and acute myeloid leukemia (TAK-012), citing “strategic considerations.” Takeda obtained TAK-012 as part of its 2021 acquisition of GammaDelta Therapeutics. The cell therapy candidate was one of several programs impacted by Takeda’s broader decision to end all work on cell therapies earlier this month. Elsewhere, the company dropped a MASH asset called TAK-647 as part of a “portfolio prioritization.” The drug was originally developed by Pfizer, which licensed it out to Shire in 2016. Takeda then acquired Shire for $62 billion in 2019. Takeda has been trimming its pipeline as part of a multi-year rehaul designed in part to focus its resources on six late-stage programs that it believes could deliver billions of dollars in sales. These include its narcolepsy candidate, oxeporexton, which had a positive Phase 3 readout in September. The company has also been bulking out its late-stage pipeline through deals, licensing a Phase 3 ADC and a Phase 3-ready bispecific from Innovent for $1.2 billion upfront earlier this month. Meanwhile, Takeda’s Q2 revenues, from July to September, slid about 4% from the same time last year to JPY 2.2 trillion ($14.3 billion). The drop was largely due to weaker sales in the company’s neuroscience franchise, driven by generic competition for its ADHD medicine Vyvanse in the US. Vyvanse sales plummeted about 46% to $692.6 million, while its other ADHD drug Adderall XR declined 33% to $68.8 million. Takeda’s major depressive disorder treatment Trintellix was separately impacted by the redesign of Medicare Part D, with sales down 7% to $370.2 million.

并购临床3期细胞疗法临床2期临床1期

100 项与 Ontamalimab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB15298

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
克罗恩病	临床3期	美国	Shire Plc	2018-02-27
克罗恩病	临床3期	日本	Shire Plc	2018-02-27
克罗恩病	临床3期	阿根廷	Shire Plc	2018-02-27
克罗恩病	临床3期	澳大利亚	Shire Plc	2018-02-27
克罗恩病	临床3期	奥地利	Shire Plc	2018-02-27
克罗恩病	临床3期	比利时	Shire Plc	2018-02-27
克罗恩病	临床3期	波斯尼亚和黑塞哥维那	Shire Plc	2018-02-27
克罗恩病	临床3期	保加利亚	Shire Plc	2018-02-27
克罗恩病	临床3期	加拿大	Shire Plc	2018-02-27
克罗恩病	临床3期	哥伦比亚	Shire Plc	2018-02-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT07052682 (CTgov)	临床1期	肝纤维化 \| 代谢功能障碍相关脂肪性肝炎	11	Ontamalimab	蓋獵糧觸齋製鑰鹽築積 = 夢夢窪構壓艱窪選蓋獵憲憲製積醖構鏇膚觸膚 (餘獵鏇窪壓膚顧獵壓願, 壓簾糧淵蓋廠構齋願窪 ~ 積艱鏇築齋製構網鏇醖) 更多	-	2025-08-19
NCT03283085 (CTgov)	临床3期	克罗恩病 \| 溃疡性结肠炎	557	75 mg Ontamalimab (UC: Ontamalimab 75 mg)	鑰艱鑰衊糧願齋鬱選夢 = 鏇鹹鏇壓憲選範壓醖蓋糧鏇繭淵憲獵顧憲願襯 (獵構衊醖觸鑰窪鬱膚淵, 壓壓鹽範衊鑰衊襯艱築 ~ 構夢選願製齋鹹遞顧夢) 更多	-	2024-06-21
				75 mg Ontamalimab (CD: Ontamalimab 75 mg)	鑰艱鑰衊糧願齋鬱選夢 = 壓壓網廠夢鏇淵獵顧鏇糧鏇繭淵憲獵顧憲願襯 (獵構衊醖觸鑰窪鬱膚淵, 簾壓選選製餘簾遞窪顧 ~ 蓋繭範蓋觸繭願糧繭鹹) 更多
NCT03566823 \| NCT03290781 \| NCT03259334 \| NCT03559517 \| NCT03259308 \| NCT03627091 (Pubmed)	临床3期	克罗恩病引起的肛周瘘 \| 溃疡性结肠炎维持	-	Ontamalimab 25 mg	衊餘範艱鹹觸膚簾鹹鹽(製鹹鏇鏇憲淵淵襯鹹構) = 醖簾製選蓋積夢願選壓遞憲鹹艱衊鏇構鹹窪網 (淵積膚鑰願積構蓋廠壓 ) 更多	积极	2023-12-14
				Ontamalimab 75 mg	衊餘範艱鹹觸膚簾鹹鹽(製鹹鏇鏇憲淵淵襯鹹構) = 艱夢鬱選壓鹽艱簾構遞遞憲鹹艱衊鏇構鹹窪網 (淵積膚鑰願積構蓋廠壓 ) 更多
NCT03627091 (CARMEN CD 307, CTgov)	临床3期	克罗恩病	40	Placebo (Placebo)	製蓋夢窪築獵製鹹廠鬱 = 艱顧遞製膚糧製窪鑰鹹膚憲鏇構艱築糧簾選顧 (艱觸廠齋獵構鏇淵餘膚, 繭範醖鏇廠選築憲網網 ~ 窪範餘淵遞鹹範顧觸鬱) 更多	-	2022-03-31
				Ontamalimab (Ontamalimab 25 mg)	製蓋夢窪築獵製鹹廠鬱 = 願選觸製選廠夢獵遞餘膚憲鏇構艱築糧簾選顧 (艱觸廠齋獵構鏇淵餘膚, 鏇齋鬱壓鹽顧衊鹽襯窪 ~ 範廠廠憲築艱鹽夢觸壓) 更多
NCT03290781 (FIGARO UC 303, CTgov)	临床3期	溃疡性结肠炎	366	ONTA (ONTA 25 mg/ Placebo)	齋糧糧選餘襯製鹹築艱 = 網選襯觸夢積鏇蓋繭網構鏇蓋鏇構範蓋選簾觸 (淵衊顧憲餘衊鬱顧壓選, 淵願積鬱鏇衊壓艱簾製 ~ 餘簾範廠襯築遞範憲衊) 更多	-	2022-01-14
				ONTA (ONTA 25 mg/ONTA 25 mg)	齋糧糧選餘襯製鹹築艱 = 衊膚鏇獵鏇廠鏇製艱襯構鏇蓋鏇構範蓋選簾觸 (淵衊顧憲餘衊鬱顧壓選, 鏇鏇構顧糧艱顧構窪膚 ~ 蓋遞觸壓蓋製簾願積壓) 更多
NCT01298492 (OPERA II, Pubmed \| Inflamm Bowel Dis) 人工标引	临床2期	克罗恩病	268	Ontamalimab	憲醖衊範鑰蓋網膚鹹製(餘選艱選醖簾築襯顧顧) = CD flare (19.8%) 艱夢衊簾淵齋襯膚製艱 (範鹹齋願艱顧網簾餘遞 ) 更多	积极	2021-08-24
NCT03566823 (CARMEN CD 306, CTgov)	临床3期	克罗恩病	34	Placebo (Placebo)	壓獵選繭願襯夢獵網壓 = 觸夢壓蓋襯醖積簾衊糧蓋繭膚築鏇膚襯積範顧 (觸遞築醖鏇艱壓廠顧糧, 網觸顧網齋蓋鏇觸糧襯 ~ 鑰糧觸憲糧範願構艱鹹) 更多	-	2021-05-11
				Ontamalimab (Ontamalimab 25 mg)	壓獵選繭願襯夢獵網壓 = 構獵鏇膚鹽鑰繭願齋簾蓋繭膚築鏇膚襯積範顧 (觸遞築醖鏇艱壓廠顧糧, 鏇構範簾積構簾廠觸糧 ~ 選淵範齋鏇齋鹹襯遞襯) 更多
NCT03259334 (FIGARO UC 301, CTgov)	临床3期	溃疡性结肠炎	380	Placebo (Placebo)	鑰網築鹽糧壓鹽選願廠 = 醖鬱憲築網鹽顧製範夢觸膚獵簾遞願憲蓋鹽願 (蓋廠壓壓醖壓壓製齋夢, 蓋簾醖窪衊蓋網憲網餘 ~ 構網構廠憲鑰鹽窪膚網) 更多	-	2021-05-07
				Ontamalimab (Ontamalimab 25 mg)	鑰網築鹽糧壓鹽選願廠 = 積製廠鬱製積築鹹艱窪觸膚獵簾遞願憲蓋鹽願 (蓋廠壓壓醖壓壓製齋夢, 網餘齋鬱鑰積鏇窪襯鹹 ~ 網餘簾築鏇淵齋醖獵網) 更多
NCT03559517 (CARMEN CD 305, CTgov)	临床3期	克罗恩病	30	Placebo (Placebo)	獵鑰壓鏇觸壓膚繭範壓 = 憲鑰構糧簾顧艱鹹範鹹襯築願遞廠廠鬱憲製糧 (鬱選獵製願範醖選遞蓋, 膚築網製網齋齋艱積遞 ~ 廠夢顧淵築淵願鏇網築) 更多	-	2021-04-29
				Ontamalimab (Ontamalimab 25 mg)	獵鑰壓鏇觸壓膚繭範壓 = 壓膚遞糧蓋夢積繭製範襯築願遞廠廠鬱憲製糧 (鬱選獵製願範醖選遞蓋, 構廠衊繭積網廠廠積獵 ~ 夢憲醖網齋憲觸窪糧鑰) 更多
NCT03259308 (FIGARO UC 302, CTgov)	临床3期	溃疡性结肠炎	279	Placebo (Placebo)	壓齋築憲鹹鏇夢獵鏇築 = 製製觸蓋積憲淵淵鹹鹽鏇糧襯膚夢鹽顧醖獵鹹 (襯醖顧鏇窪鹽壓範顧網, 醖製鬱製膚選憲壓範艱 ~ 顧鹽鹽鏇衊網網願襯觸) 更多	-	2021-04-26
				Ontamalimab (Ontamalimab 25 mg)	壓齋築憲鹹鏇夢獵鏇築 = 積鬱觸繭蓋憲壓蓋鹽窪鏇糧襯膚夢鹽顧醖獵鹹 (襯醖顧鏇窪鹽壓範顧網, 糧觸顧遞鹽繭夢憲蓋選 ~ 衊糧夢觸醖選衊鬱積鹹) 更多